{"id":"NCT00440999","sponsor":"Medicines for Malaria Venture","briefTitle":"Pyronaridine Artesunate (3:1) in Children and Adults With Acute Plasmodium Vivax Malaria","officialTitle":"A Phase III Comparative (Double-blind, Double-dummy) Randomised Multicentre Study to Assess the Safety & Efficacy of Oral Pyronaridine Artesunate (180:60 mg) Versus Chloroquine (155 mg) in Children & Adult Patients With Acute Vivax Malaria","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-03","primaryCompletion":"2008-04","completion":"2008-09","firstPosted":"2007-02-27","resultsPosted":"2021-09-20","lastUpdate":"2021-11-02"},"enrollment":456,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Malaria"],"interventions":[{"type":"DRUG","name":"Pyronaridine artesunate","otherNames":["Pyramax"]},{"type":"DRUG","name":"Chloroquine","otherNames":[]}],"arms":[{"label":"pyronaridine artesunate","type":"EXPERIMENTAL"},{"label":"chloroquine","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to compare the efficacy and safety of the fixed combination of pyronaridine artesunate (PyramaxÂ®, PA) (180:60 mg) with that of standard chloroquine therapy in children and adults with acute, uncomplicated Plasmodium vivax malaria.","primaryOutcome":{"measure":"Crude Cure Rate on Day 14","timeFrame":"Day 14","effectByArm":[{"arm":"Pyronaridine Artesunate","deltaMin":217,"sd":null},{"arm":"Chloroquine","deltaMin":209,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"3 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":5,"countries":["Cambodia","India","Indonesia","Thailand"]},"refs":{"pmids":["21267072","26666916","23433102"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":228},"commonTop":["Headache","Myalgia","Anorexia","Fatigue","Nasopharyngitis"]}}